Sanofi-Aventis Eyes April User Fee Goal For Anti-Arrythmic Dronedarone
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In advance of an April user fee deadline for Sanofi-Aventis’ anti-arrythmic dronedarone, the firm is positioning the compound as a successor to its Cordarone (amiodarone) with increased tolerability.